We are rapidly advancing our CAR-NK cell therapies toward the clinic to address solid tumors.
Lead Programs
CAT-248: CD70 CAR-NK Cell Therapy
CAT-248 is our off-the-shelf CAR-NK cell therapy targeting CD70 positive tumors. CAT-248 has been engineered with four functional modifications: an optimized CAR that targets CD70; an IL-15 cytokine that promotes persistence and enhanced NK cell activity, a TME-switch that neutralizes the effects of the TGFβ immunosuppressive signal found in the tumor microenvironment, and the elimination of CD70 expression to enable scalable manufacturing. Our initial clinical studies with CAT-248 will target renal cell carcinoma.
CAT-179: HER2 CAR-NK Cell Therapy
CAT-179 is our off-the-shelf CAR-NK cell therapy targeting HER2 positive solid tumors. CAT-179 has been engineered with three functional modifications: an optimized CAR that targets HER2, an IL-15 cytokine that promotes persistence and enhanced NK cell activity, and a TME-switch that neutralizes the effects of the TGFβ immunosuppressive signal found in the tumor microenvironment. Our initial clinical studies with CAT-179 will target breast cancer and gastric cancer.
Research Pipeline
We are deploying our modular TAILWIND® platform to develop additional CAR-NK therapies for solid tumors by leveraging our suite of innovative TME switches, optimized CAR architecture, and versatile manufacturing platform.